Kit ɗin Gwajin Neutralizing Gwajin COVID Antibody
Kit ɗin Gwajin Neutralizing Gwajin COVID Antibody
Gwajin rigakafin COVID-19 na Neutralizing Ab Rapid Test ana amfani da gwaje-gwajen immunochromatographic na baya don gano SARS-COV-2 neutralizing antibody (NAb), wanda za'a iya amfani dashi don tantance matsayin rigakafi bayan kamuwa da cuta ko alurar riga kafi.
KA'IDA
Gwajin gaggawa na SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) don gano ƙwayoyin rigakafi ne ga SARS-CoV-2 ko rigakafin sa. Mai karɓar mai karɓar angiotensin yana canza enzyme-2 (ACE2) an lullube shi a cikin yankin layin gwaji da yanki mai ɗaure mai karɓa (RBD) tare da abubuwan da ke nuna. Yayin gwaji, idan akwai ƙwayoyin rigakafi na SARS-CoV-2 a cikin samfurin, zai amsa tare da furotin RBD-barbashi kuma ba zai amsa da furotin da aka riga aka rufa ba ACE2. Cakuda daga nan yana ƙaura zuwa sama akan membrane chromatographically ta hanyar aikin capillary kuma ba zai kama shi da antigen da aka riga aka rufa ba.
Gwajin gaggawa na SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) yana ƙunshe da barbashi mai rufaffiyar furotin RBD. Sunadaran ACE2 an lullube su a yankin layin gwaji
Siffar
A. Gwajin jini: jini, plasma, jini duka da jinin bakin yatsa duk suna samuwa.
B. Ana buƙatar ƙananan samfurori. Serum, plasma 10ul ko duka jini 20ul ya isa.
C. Gwajin rigakafin gaggawa tare da mintuna 10.
Takaddun shaida don Neutralizing AB Antibodies gwajin sauri
CE An Amince
Jerin farin na kasar Sin ya amince da Neutralizing Antibody Rapid Tes
Tsarin Gwaji
Mai Karatun Sakamako
IYAKA
1. The SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) don amfani ne kawai don gano cutar ta in vitro. Ya kamata a yi amfani da wannan gwajin don gano ƙwayoyin rigakafin ƙwayoyin cuta zuwa SARS-CoV-2 ko alluran rigakafinta a cikin jini, jini, ko plasma baki ɗaya.
2. The SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) kawai zai nuna kasancewar kawar da ƙwayoyin rigakafi na SARS-CoV-2 a cikin samfurin kuma bai kamata a yi amfani da shi azaman kawai ma'auni na hanyar gano titer na antibody ba.
3. A cikin majinyatan da aka murmure, adadin adadin ƙwayoyin rigakafi na SARS-CoV-2 na iya zama sama da matakan ganowa. Ba za a iya la'akari da ingancin wannan kima a matsayin shirin rigakafin nasara ba.
4. Ba za a iya amfani da ci gaba da kasancewa ko rashi na rigakafi ba don ƙayyade nasara ko gazawar jiyya.
5. Sakamako daga marasa lafiya na rigakafi ya kamata a fassara su da hankali.
6. Kamar yadda yake tare da duk gwaje-gwaje na bincike, duk sakamakon dole ne a fassara shi tare da wasu bayanan asibiti da ke samuwa ga likita.
GASKIYA
Intra-Assay
An ƙaddara madaidaicin cikin-gudu ta amfani da kwafi 15 na samfurori guda biyu: mara kyau, da kuma ingantaccen maganin rigakafi na RBD (5ug/mL). An gano samfuran daidai>99% na lokacin.
Inter-Assay
Ƙididdigar masu zaman kansu guda 15 sun ƙaddara daidaitattun tsaka-tsaki a kan samfurori guda biyu: mara kyau, da tabbatacce. An gwada kuri'a daban-daban guda uku na SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) ta amfani da waɗannan samfuran. An gano samfuran daidai>99% na lokacin.
HANKALI
1.Don in-vitro diagnostic amfani kawai.
2.Kada a yi amfani da kit fiye da ranar karewa.
3.Kada ku haɗa abubuwan da aka gyara daga kits tare da lambar kuri'a daban-daban.
4.Avoid microbial gurbatawa na reagents.
5.Yi amfani da gwajin da wuri-wuri bayan buɗewa don kare shi daga danshi.